JP2023539715A - 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ - Google Patents
抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ Download PDFInfo
- Publication number
- JP2023539715A JP2023539715A JP2022580310A JP2022580310A JP2023539715A JP 2023539715 A JP2023539715 A JP 2023539715A JP 2022580310 A JP2022580310 A JP 2022580310A JP 2022580310 A JP2022580310 A JP 2022580310A JP 2023539715 A JP2023539715 A JP 2023539715A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- imidazo
- antibody
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043474P | 2020-06-24 | 2020-06-24 | |
| US63/043,474 | 2020-06-24 | ||
| PCT/IB2021/055549 WO2021260580A1 (en) | 2020-06-24 | 2021-06-23 | Combination of antibody-drug conjugate and atm inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539715A true JP2023539715A (ja) | 2023-09-19 |
| JP2023539715A5 JP2023539715A5 (enExample) | 2024-06-28 |
Family
ID=76730927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580310A Pending JP2023539715A (ja) | 2020-06-24 | 2021-06-23 | 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230256110A1 (enExample) |
| EP (1) | EP4171651A1 (enExample) |
| JP (1) | JP2023539715A (enExample) |
| CN (1) | CN116194109A (enExample) |
| TW (1) | TW202216209A (enExample) |
| WO (1) | WO2021260580A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121038817A (zh) * | 2023-04-10 | 2025-11-28 | 第一三共株式会社 | 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合 |
| AU2024263367A1 (en) * | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015115091A1 (ja) * | 2014-01-31 | 2015-08-06 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2017514877A (ja) * | 2014-05-08 | 2017-06-08 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | イミダゾ［４，５−ｃ］キノリン−２−オン化合物および癌の処置におけるそれらの使用 |
| JP2018531226A (ja) * | 2015-09-17 | 2018-10-25 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 癌の治療のための血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターとしての８−［６−［３−（アミノ）プロポキシ］−３−ピリジル］−１−イソプロピル−イミダゾ［４，５−ｃ］キノリン−２−オン誘導体 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| ATE370961T1 (de) * | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| AR024464A1 (es) | 1999-06-25 | 2002-10-02 | Genentech Inc | Anticuerpos anti-erbb2 humanizados. |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| MXPA04007809A (es) | 2002-02-25 | 2004-10-15 | Kudos Pharm Ltd | Piranonas utiles como inhibidores de ataxia-telangetaxia mutada. |
| KR20060066722A (ko) | 2003-08-13 | 2006-06-16 | 쿠도스 파마슈티칼스 리미티드 | 아미노피론 및 ａｔｍ억제제로서의 이의 용도 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| JP6282232B2 (ja) | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド，ボルティモア | 抗体及びそのＦｃフラグメントの酵素化学的糖鎖改変 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| PL3277681T3 (pl) | 2015-04-02 | 2019-10-31 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| CA2990572C (en) | 2015-06-29 | 2022-07-26 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| GB201519406D0 (en) | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201604182D0 (en) | 2016-03-11 | 2016-04-27 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| PE20181895A1 (es) | 2016-03-21 | 2018-12-11 | Astrazeneca Ab | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer |
| WO2017162611A1 (en) | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Quinoline-3-carboxamide compounds and their use in treating cancer |
| US20190119270A1 (en) | 2016-04-07 | 2019-04-25 | Astrazeneca Ab | N-Oxide Compound and Its Use in Treating Cancer |
| GB201608227D0 (en) | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| JOP20190209A1 (ar) | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| EP3677589B1 (en) | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| CN111344293A (zh) | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
-
2021
- 2021-06-23 CN CN202180050399.2A patent/CN116194109A/zh active Pending
- 2021-06-23 WO PCT/IB2021/055549 patent/WO2021260580A1/en not_active Ceased
- 2021-06-23 JP JP2022580310A patent/JP2023539715A/ja active Pending
- 2021-06-23 US US18/012,900 patent/US20230256110A1/en active Pending
- 2021-06-23 EP EP21736709.3A patent/EP4171651A1/en active Pending
- 2021-06-23 TW TW110122960A patent/TW202216209A/zh unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015115091A1 (ja) * | 2014-01-31 | 2015-08-06 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| JP2017514877A (ja) * | 2014-05-08 | 2017-06-08 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | イミダゾ［４，５−ｃ］キノリン−２−オン化合物および癌の処置におけるそれらの使用 |
| JP2018531226A (ja) * | 2015-09-17 | 2018-10-25 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 癌の治療のための血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターとしての８−［６−［３−（アミノ）プロポキシ］−３−ピリジル］−１−イソプロピル−イミダゾ［４，５−ｃ］キノリン−２−オン誘導体 |
Non-Patent Citations (2)
| Title |
|---|
| CLINICAL CANCER RESEARCH, vol. 22, no. 20, JPN6025024361, 2016, pages 5097 - 5108, ISSN: 0005619340 * |
| CLINICAL CANCER RESEARCH, vol. 25, no. 22, JPN6025024362, 2019, pages 6581 - 6589, ISSN: 0005619339 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116194109A (zh) | 2023-05-30 |
| US20230256110A1 (en) | 2023-08-17 |
| WO2021260580A1 (en) | 2021-12-30 |
| EP4171651A1 (en) | 2023-05-03 |
| TW202216209A (zh) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7793556B2 (ja) | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ | |
| US20230256110A1 (en) | Combination of antibody-drug conjugate and atm inhibitor | |
| KR102905497B1 (ko) | 항체-약물 컨쥬게이트와 parp 저해제의 조합 | |
| US20250064967A1 (en) | Combination of antibody-drug conjugate and atr inhibitor | |
| US20230233540A1 (en) | Combination of antibody-drug conjugate and cdk9 inhibitor | |
| US20250025568A1 (en) | Combination of antibody-drug conjugate and parp1 selective inhibitor | |
| US20250161305A1 (en) | Combination of antibody-drug conjugate and rasg12c inhibitor | |
| EP4696332A1 (en) | Combination of anti-b7-h3 antibody-drug conjugate with atr inhibitor or atm inhibitor | |
| EA049478B1 (ru) | Комбинация конъюгата антитела и лекарственного средства и ингибитора atr | |
| EA053102B1 (ru) | Комбинация конъюгата антитела и лекарственного средства и ингибитора atr | |
| EA052190B1 (ru) | Комбинация конъюгата антитела и лекарственного средства и селективного ингибитора parp1 | |
| HK40070611A (en) | Combination of anti-her2 antibody and cdk inhibitor for tumor treatment | |
| HK40064358A (en) | Combination of antibody-drug conjugate with parp inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240620 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240620 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250530 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250911 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251217 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260113 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260513 |